A comparison of the influence of N-isopropyl and N-tert butyl substituents on the affinity of ligands for sinoatrial β-adrenoceptors in rat atria and β-adrenoceptors coupled to the adenylyl cyclase in kitten ventricle

  • A. J. Kaumann
  • T. H. Morris
  • L. Birnbaumer
Article

Summary

The potencies as β-adrenoceptor blockers of KL 1006 (the N-isopropyl analogue of bupranolol), pindolol, propranolol and carazolol were compared with potencies of their corresponding tert. butyl analogues bupranolol, tert. butylpindolol, tert. butylpropranol and ter. butylcarazolol.

Experiments were carried out at 32.5° C in rat right atria — assessing β-adrenoceptor dependent chronotropic effects — and kitten ventricular membranes — assessing β-adrenoceptor dependent stimulation of adenylyl cyclase — from reserpine pretreated animals.
  1. 1.

    The effects of (−)-isoprenaline on these two systems were antagonized competitively by each of the 8 ligands.

     
  2. 2.

    None of the 8 ligands caused stimulation or depression of basal adenylyl cyclase activity at concentrations causing antagonism of the effects of (−)-isoprenaline.

     
  3. 3.

    Pindolol, tert. butylpindolol, carazolol and tert. butylcarazolol were weak partial agonists in rat atria. concentrations of these ligands for producing significant stimulation were higher than those causing significant antagonism of the chronotropic effects of (−)-isoprenaline.

     
  4. 4.

    Bupranolol, tert. butylpindolol, tert. butylpropranolol and tert. butylcarazolol were 6.6, 3.0, 3.2 and 1.1. times more potent as β-adrenoceptor antagonists in rat atria than their corresponding N-isopropyl analogues, respectively.

     
  5. 5.

    Bupranolol, tert. butylpindolol, tert. butylpropranolol and tert. butylcarazolol were 4.8, 3.0, 2.7 and 0.6 times more potent as β-adrenoceptor antagonists in kitten membranes than their corresponding N-isopropyl analogues, respectively.

     
  6. 6.

    The enhanced affinity for myocardial β-adrenoceptors of N-tert. butyl ligands (with respect to the affinity of the corresponding N-isopropyl ligands) appears to be inversely correlated with the size of the ring of the ligands.

     

Key words

N-isopropyl and N-tert. butyl ligands β-Adrenoceptor-affinity Heart ventricular adenylyl cyclase Rat sinoatrial node 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Åblad, B., Brogård, M., Ek, L.: Pharmacological properties of H56/28 — a β-adrenergic receptor antagonist. Acta Pharmacol. Toxicol. (Kbh.) 25, Suppl. 2, 9–40 (1967)Google Scholar
  2. Ahlquist, R. P.: A study of the adrenotropic receptors. Am. J. Physiol. 153, 586–599 (1948)Google Scholar
  3. Arunlakshana, O., Schild, H. O.: Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14, 48–58 (1959)Google Scholar
  4. Barrett, A. M., Carter, J.: Comparative chronotropic activity of β-adrenoceptive antagonists. Br. J. Pharmacol. 40, 373–381 (1970)Google Scholar
  5. Bilski, A. J., Wale, J. L.: Two types of intrinsic sympathomimetic activity with β-adrenoceptor blocking drugs. Br. J. Pharmacol. 56, 362P (1976)Google Scholar
  6. Birnbaumer, L., Kaumann, A. J.: Attempts at modeling a β-adrenoceptor-responsive adenylyl cyclase system. Proceedings of the VIth International Symposium on Medicinal Chemistry, (M. A. Simkins, ed.), Oxford: Costwold Press, in press 1979Google Scholar
  7. Black, J. W., Stephenson, J. S.: Pharmacology of a new adrenergic β-receptor blocking compound (Nethalide). Lancet 1962 II, 311–314Google Scholar
  8. Black, J. W., Crowther, A. F., Shanks, R. G., Dornhorst, A. C.: A new adrenergic β-receptor antagonist. Lancet 1964 II, 1080–1081Google Scholar
  9. Black, J. W., Duncan, W. A. M., Shanks, P. G.: Comparison of some properties of pronethalol and propranolol. Br. J. Pharmacol. 25, 577–591 (1965)Google Scholar
  10. Brunner, H., Hedwall, P. R., Meier, M.: Pharmakologische Untersuchungen mit 1-Isopropylamino-3-(O-allyloxyphenoxy)-2-propanol-hydrochlorid, einem adrenergischen β-Rezeptorenblocker. Arzneim.-Forsch. 18, 164–170 (1968)Google Scholar
  11. Carlsson, E., Åblad, B., Brändström, A., Carlsson, B.: Differentiated blockade of the chromotropic effects of various adrenergic stimuli in the cat heart. Life Sci. 11, 953–958 (1972)Google Scholar
  12. Cheymol, G., Honnorat, C., Schmitt, H.: Pharmacological effects of two new β-adrenoceptor blocking drugs: Kö 1366 and Kö 1313. Eur. J. Pharmacol. 17, 341–351 (1972)Google Scholar
  13. Crowther, A. F., Howe, R., McLoughlin, B. J., Mallion, K. B., Smith, L. H., Turner, R. W.: β-Adrenergic blocking agents. 12. Heterocyclic compounds related to propranolol. J. Med. Chem. 15, 260–266 (1972)Google Scholar
  14. Femmer, K., Bürkner, U., Grünheid, K., Röllig, H.: Struktur-Wirkungsbeziehungen bei Phenoxyalkanolaminderivaten mit selektiver β1-Rezeptorenblockade. Pharmazie 30, 638–642 (1975)Google Scholar
  15. Fothergill, G. A., Francis, R. J., Hamilton, T. C., Osbond, J. M., Parkes, M. W.: Bufuralol, a new β-adrenoceptor blocking agent. Experientia 31, 1322–1323 (1975)Google Scholar
  16. Giudicelli, J. F., Schmitt, H., Boissier, J. R.: Studies on dl-4-(2-hydroxy-3-isopropylamino-propoxy)-indole (LB 46), a new potent β-adrenergic blocking compound. J. Pharmacol. Exp. Ther. 168, 116–126 (1969)Google Scholar
  17. Kaplan, H. R., Lasala, S. A., Robson, R. D.: Oral β-adrenoceptor blocking activity of bunolol and its optical isomers. Eur. J. Pharmacol. 16, 237–240 (1971)Google Scholar
  18. Kaumann, A. J.: Potentiation of the effects of isoprenaline and noradrenaline by hydrocortisone in cat heart muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 273, 134–153 (1972)Google Scholar
  19. Kaumann, A. J.: Adrenergic receptors of cardiac muscle: Two different mechanisms of β-blockers as partial agonists. Internat. Union of Biochemistry, Symposium No. 52, Acta Physiol. Lat.-Am. 32, 235–236 (1973)Google Scholar
  20. Kaumann, A. J.: Some differences between heart β-adrenoceptors of reserpine-pretreated rats (Wistar II) and frogs (Xenopus laevis). Naunyn-Schmiedeberg's Arch. Pharmacol. 297, R49 (1977a)Google Scholar
  21. Kaumann, A. J.: Relaxation of heart muscle by catecholamines and by dibutyryl cyclic adenosine 3′,5′-monophosphate. Similarity of β-adrenoceptors mediating contractile and relaxant effects of catecholamines in kitten papillary muscle. Naunyn-Schmiederg's Arch. Pharmacol. 296, 205–215 (1977b)Google Scholar
  22. Kaumann, A. J.: On spare β-adrenoceptors for intropic effects of catecholamines in kitten ventricle. Naunyn-Schmiedeberg's Arch. Pharmacol. 305, 97–102 (1978)Google Scholar
  23. Kaumann, A. J., Birnbaumer, L.: Characteristics of the adrenergic receptor coupled to myocardial adenylyl cyclase. Stereospecificity and determination of apparent affinity constants for β-blockers. J. Biol. Chem. 249, 7874–7885 (1974)Google Scholar
  24. Kaumann, A. J., Blinks, J. R.: Comparative potencies of β-adrenergic blocking agents on isolated heart muscle. Fed. Proc. 26, 401 (1967)Google Scholar
  25. Kaumann, A. J., Bojar, H.: Relationship between the cellular number of occupied β-adrenoceptors and inotropic effects of catecholamines in hearts of reserpine-pretreated kittens. Proc. 7th International Congress of Pharmacology, p. 916, Paris, July 16–21, 1978Google Scholar
  26. Kaumann, A. J., Friedenthal, M., Blinks, J. R.: Análisis de la acción bloqueante de antagonistas β-adrenérgicos en músculo cardíaco aislado. Medicina (B. Aires) 30, 596–597 (1970)Google Scholar
  27. Kaumann, A. J., Wittmann, R., Birnbaumer, L., Hoppe, B. H.: Activation of myocardial β-adrenoceptors by the nitrogen-free low affinity ligand 3′,4′-dihydro-2-methylpropiophenone (U-0521). Naunyn-Schmiedeberg's Arch. Pharmacol. 296, 217–228 (1977)Google Scholar
  28. Kaumann, A. J., Birnbaumer, L., Wittmann, R.: Heart β-adrenoceptors. In: Receptors and Hormone Action, Vol. III, pp. 133–177, (O'Malley, B. W., Birnbaumer, L., eds.). New York: Academic Press 1978Google Scholar
  29. Kenakin, T. P., Black, J. R.: The pharmacological classification of practolol and chloropractolol. Mol. Pharmacol. 14, 607–623 (1978)Google Scholar
  30. Lemoine, H., Kaumann, A. J.: The affinity of carazolol for myocardial and tracheal β-adrenoceptors activated by (−)-isoprenaline. Naunyn-Schmiedeberg's Arch. Pharmacol. 302, P53 (1978)Google Scholar
  31. Levy, B.: Comparison of the β-receptor blocking properties of two analogs of dichloroisoproterenol (DCI). J. Pharmacol. Exp. Ther. 186, 123–133 (1973)Google Scholar
  32. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265–275 (1951)Google Scholar
  33. Marano, M., Kaumann, A. J.: On the statistics of drug-receptor constants for partial agonists. J. Pharmacol. Exp. Ther. 198, 518–525 (1976)Google Scholar
  34. Marsh, D. F., Pelletier, M. H., Ross, C. A.: The comparative pharmacology of the N-alkylarterenols. J. Pharmacol. Exp. Ther. 92, 108–120 (1948)Google Scholar
  35. Meyer, R. F., Stratton, C. D., Hastings, S. G., Corey, R. M.: β-Adrenergic blocking agents. Nitrogen heteroaryl-substituted 2-propanolamines and ethanolamines. J. Med. Chem. 16, 1113–1116 (1973)Google Scholar
  36. Moran, N. C., Perkins, M. E.: Adrenergic blockade of the mammalian heart by a dichoro analogue of isoproterenol. J. Pharmacol. Exp. Ther. 124, 223–237 (1978)Google Scholar
  37. Morris, T. H., Birnbaumer, L., Kaumann, A. J.: High affinity of carazolol for β-adrenoceptors coupled to the adenylyl cyclase in ventricular myocardium of kitten and Xenopus laevis. Naunyn-Schmiedeberg's Arch. Pharmacol. 303, 295–297 (1978)Google Scholar
  38. Mylecharane, E. J., Raper, C.: β-Receptor blocking and cardiodepressant actions of 2-cyanophenoxypropanolamines. Eur. J. Pharmacol. 16, 14–20 (1971)Google Scholar
  39. Nakanishi, M., Muro, T., Chihara, H., Imamura, H., Nakao, T.: Studies on cardiovascular drugs. 5. 1-amino-3-phenoxy-2-propanol derivatives as β-adrenergic blocking agents. J. Med. Chem. 15, 45–48 (1972)Google Scholar
  40. Powell, C. E., Slater, I. H.: Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J. Pharmacol. Exp. Ther. 122, 480–488 (1958)Google Scholar
  41. Salomon, Y., Londos, C., Rodbell, M.: A highly sensitive adenylate cyclase assay. Anal. Biochem. 58, 541–548 (1974)Google Scholar
  42. Schweiger, J., Nicolescu, R. F., Rahn, K. H.: Quantitative Bestimmung der β-Rezeptorenblockade bein Menschen. Verh. Dtsch. Ges. Inn. Med. 78, 1544–1547 (1972)Google Scholar
  43. Scriabine, A., Torchiana, M. L., Stavorski, J. M., Ludden, C. T., Minsker, D. H., Stone, C. A.: Some cardiovascular effects of timolol, a new β-adrenergic blocking agent. Arch. Int. Pharmacodyn. 205, 76–93 (1973)Google Scholar
  44. Stephenson, R. P.: A modification of receptor theory. Br. J. Pharmacol. 11, 379–393 (1956)Google Scholar
  45. Weinstock, L. M., Mulvey, D. M., Tull, R.: Synthesis of the β-adrenergic blocking agent timolol from optically active precursors. J. Org. Chem. 41, 3121–3124 (1976)Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • A. J. Kaumann
    • 1
    • 2
  • T. H. Morris
    • 1
    • 2
  • L. Birnbaumer
    • 2
  1. 1.Lehrstuhl für Klinische PhysiologiePhysiologisches Institut der Universität DüsseldorfDüsseldorfFederal Republic of Germany
  2. 2.Department of Cell BiologyBaylor College of MedicineHoustonUSA

Personalised recommendations